A conversation with Dr. Greg Campbell.
A conversation with Dr. Greg Campbell.
复制标题
与格雷格·坎贝尔博士的对话。
DOI：
10.1080/10543406.2016.1226331
复制
发表时间：
2016
影响因子：
1.1
通讯作者：
Yue,LillyQ
中科院分区：
文献类型：
--
作者：
Liu,Aiyi;Yue,LillyQ
格雷戈里坎贝尔博士于1976年获得佛罗里达州立大学数理统计学博士学位。完成研究生学业后，坎贝尔博士在普渡大学统计系担任助理教授，后来加入了美国国立卫生研究院的内部计划，在那里他被晋升为终身高级研究员，他曾担任统计和数学方法实验室的代理主任，然后担任分析生物测定科科长。坎贝尔博士于1995年加入美国食品药品监督管理局（FDA），并担任FDA器械和放射卫生中心（CDRH）监督和生物统计学办公室生物统计部主任，直至2015年6月底从联邦政府退休。他非凡的领导能力使该司从18名数理统计员发展到52名。他为公共卫生、FDA和医疗器械行业做出了卓越的贡献，领导部门为整个CDRH提供统计支持，特别是对FDA上市前器械申报的统计审查，为市场带来了许多重要和创新的医疗器械。在他近33年的联邦服务期间，坎贝尔博士一直保持着高水平的专业精神和奉献精神。由于他作为医疗器械领域统计创新的推动力和伟大领导者的杰出贡献，医疗器械评价和监管科学的进程已经大大塑造。他的开创性工作和持续努力，在贝叶斯统计，因果推理，自适应设计，缺失数据和诊断测试方法的监管环境中适应和推进实施，对公共卫生产生了显著，深远和持久的影响，并导致临床研究设计的完整性和研究结果的可信度以及一致性，透明度，FDA和行业监管决策的有效性和可预测性。坎贝尔博士被公认为监管科学领域的国际知名统计领导者。坎贝尔博士曾担任国际生物统计学会北美东部地区（ENAR）、临床试验学会和FDA统计协会（FDASA）的领导职务。他在医疗器械和诊断统计界的建立中发挥了杰出的领导作用，并在美国统计协会（阿萨）医疗器械和诊断部门（MDD）的形成中发挥了重要作用。坎贝尔博士是卫生与公众服务部著名的高级生物医学研究服务（SBRS）的成员超过10年，并在SBRS资格认证委员会任职15年。他自1999年以来一直是美国统计协会的会员。
Dr. Gregory Campbell received his PhD in Mathematical Statistics from the Florida State University in 1976. After his completion of graduate studies, Dr. Campbell took a faculty position as an assistant professor in the Department of Statistics at Purdue University, and later joined the intramural program of the National Institutes of Health, where he was promoted to a senior investigator with tenure, and he served as the Acting Chief for the Laboratory of Statistical and Mathematical Methodology, and then Chief of the Analytical Biometrics Section. Dr. Campbell joined the Food and Drug Administration (FDA) in 1995, and served as the Director of the Division of Biostatistics in the Office of Surveillance and Biometrics of the Center for Devices and Radiological Health (CDRH) at the FDA until his retirement from the federal government at the end of June 2015. His extraordinary leadership has resulted in the growth of the Division from 18 mathematical statisticians to 62 in five branches. He has made exceptional contributions to public health, the FDA, and medical device industry by leading the Division to provide statistical support to CDRH as a whole and, in particular, the statistical reviews of FDA’s pre-market device submissions, bringing in numerous important and innovative medical devices to the market place.During his nearly 33 years of federal service, Dr. Campbell has sustained high levels of professionalism and dedication. Because of his distinguished contributions as a driving force and a great leader in statistical innovations in the medical device world, the course of medical device evaluation and regulatory science has been greatly shaped. His pioneer work and sustained efforts in adapting and advancing the implementation in a regulatory environment of Bayesian statistics, causal inference, adaptive design, missing data, and diagnostic test methodology have made phenomenal, far reaching, and long-lasting impacts to public health and resulted in the increase of the integrity of clinical study design and the creditability of study results as well as the consistency, transparency, effectiveness, and predictability of regulatory decision-making for the FDA and industry. Dr. Campbell has been recognized as an internationally renowned statistical leader in regulatory science. Dr. Campbell served in leadership positions for the Eastern North American Region (ENAR) of the International Biometric Society, the Society for Clinical Trials, and the FDA Statistical Association (FDASA). He played a distinguished leadership role in the establishment of the statistical community of medical devices and diagnostics, and was instrumental in the formation of the American Statistical Association (ASA)’s Section on Medical Devices and Diagnostics (MDD). Dr. Campbell was a member for over 10 years of the prestigious Senior Biomedical Research Service (SBRS) in the Department of Health and Human Services, and also served for 15 years on the SBRS credentialing committee. He has been a Fellow of the American Statistical Association since